New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities
Indivior Pharmaceuticals released a new cost impact model showing that their extended-release monthly injectable buprenorphine, SUBLOCADE®, could significantly reduce staff time and related costs in jails and prisons compared to other opioid use disorder medications. The model suggests reduced staffing needs and operational costs, potentially enhan…